Pipotiazine Palmitate
drugOn this page
Also known as 19552 RPIL-19552PiportilPiportil depotPipothiazinePipotiazinaPipotiazinePipotiazine palmitic esterRP 19552RP-19552SID144206970PIPOTIAZINE-PALMITATE
Summary
Pipotiazine Palmitate (CHEMBL2106439) is an approved small molecule (ATC N05AC04); indicated across 1 condition including psychotic disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: N05AC04
- Indications: 1 condition
- Chemistry: 714.1 Da · C40H63N3O4S2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2106439 |
| Name | Pipotiazine Palmitate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 37767 |
| ATC | N05AC04 |
| Molecular formula | C40H63N3O4S2 |
| Molecular weight | 714.1 |
| InChIKey | KTOYYUONFQWSMW-UHFFFAOYSA-N |
SMILES: CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C
IUPAC name: 2-[1-[3-[2-(dimethylsulfamoyl)phenothiazin-10-yl]propyl]piperidin-4-yl]ethyl hexadecanoate
Also known as: 19552 RP, IL-19552, Piportil, Piportil depot, Pipothiazine, Pipotiazina, Pipotiazine, Pipotiazine palmitate, Pipotiazine palmitic ester, RP 19552, RP-19552, PIPOTIAZINE PALMITATE
Patent coverage: 104 distinct patent families (351 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 341 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| psychotic disorder | 4 | MONDO:0005485 | EFO:0005407 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: psychotic disorder